In a Westlaw Practical Law Q&A column, life sciences regulatory & compliance partner Joshua Oyster and associate Helen Ryan reviewed the federal legal and regulatory framework that controls the research, approval and marketing of psychedelic drug products.
The Q&A addresses topics such as the types of drugs that are categorized under the term “psychedelic”, the role of the Food and Drug Administration and the Drug Enforcement Administration in authorizing and controlling the use of psychedelics for therapeutic medical purposes, including during the research phase of drug development, recent litigation, and potential legislation to make psychedelics more accessible to the medical community.
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.